Acquisition Thesis
Healthcare is a Marathon,
Not a Sprint.
Our 10-year fund structure balances disciplined capital deployment with the patience required to build a national healthcare platform.
Our Investment Thesis
The UK lower-mid-market healthcare sector is highly fragmented. Independent regional clinics, diagnostic chains, and specialist hubs operate at sub-scale with single-digit margins, burdened by analog workflows and expensive outsourced services. Meanwhile, Large-Cap PE firms (Bridgepoint, CVC) compete for £1bn+ assets at 9x-11x entry multiples, leaving the £20m–£50m segment largely ignored.
Ottimo Healthcare Fund I targets this valuation gap. We acquire these sub-scale assets at 6x–7x EV/EBITDA, integrate them into our proprietary tech-enabled operating playbook (Medroid AI + Rainbow Diagnostics), and drive rapid 30%+ EBITDA expansion. The result: a consolidated, tech-enabled platform generating £30m+ EBITDA that commands a premium exit multiple from Large-Cap PE or strategic acquirers.
“We capture the multiple arbitrage between fragmented clinics and integrated platforms.”
This is not financial engineering. It's operational excellence led by clinicians who understand healthcare delivery from the inside. Our 10-year fund structure (5-year investment period, 5-year harvest period) provides the runway to execute this buy-and-build strategy methodically, creating value for our LPs through disciplined capital deployment.
Owning the Patient Pathway
Vertical integration across the continuum of care creates operational synergies, improves clinical outcomes, and builds defensible market positions.
Pathology & Diagnostics
Laboratory testing, blood sciences, and diagnostic imaging that drive clinical decisions.
Primary Care
GP practices and community health centres providing frontline patient access.
Specialist Surgery
Orthopaedic, ophthalmology, and other specialist surgical services.
Rehabilitation
Post-operative recovery and physiotherapy services completing the care cycle.
UK Geographic Focus
Targeting the highly fragmented UK lower-mid-market healthcare sector with a disciplined buy-and-build consolidation strategy.
London & South East
Primary focus on London, South East, and Home Counties where private healthcare demand is strongest. Proximity to affluent demographics and established private pay infrastructure.
Fragmented Market
The UK lower-mid-market (£20m-£50m EV) is highly fragmented with retiring founder-owned clinics, sub-scale diagnostic chains, and independent specialist hubs presenting attractive consolidation opportunities.
NHS Tailwinds
7.4m+ NHS waiting list backlog drives surging private patient demand. Private healthcare is transitioning from discretionary luxury to absolute necessity for the UK middle class.
Target Market Opportunity
£20m–£50m EV
Entry: 6x–7x EBITDA | Exit: 10x–12x EBITDA